AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial

AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.Reuters Health Information (Source: Medscape Allergy Headlines)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2zlKhnw